For the treatment of stroke, scutellarin was reported to have therapeutic effects on cerebral ischemia by activating the astrocytic Janus kinase 2/signal transducer and activator of transcription 3 (JAK2/STAT3) signalling pathway [161], and by reducing the infarct cerebral tissue area in middle cerebral artery occlusion (MCAO) rats [162]. Here, JAK2 is linked to stroke disorder.